Rethinking Solventum – Balancing Technicals with Fundamentals

By Susan Ramirez • Monday, August 12 15:09 • Permanent Link

Large-cap Health Care company Solventum has moved -4.4% so far today on a volume of 719,796, compared to its average of 1,827,258. In contrast, the S&P 500 index moved -0.0%.

Solventum trades -3.83% away from its average analyst target price of $60.25 per share. The 4 analysts following the stock have set target prices ranging from $54.0 to $64.0, and on average have given Solventum a rating of hold.

If you are considering an investment in SOLV, you'll want to know the following:

Solventum has moved -12.3% over the last year, and the S&P 500 logged a change of 19.0%
Based on its trailing earnings per share of 3.96, Solventum has a trailing 12 month Price to Earnings (P/E) ratio of 14.6 while the S&P 500 average is None
SOLV has a forward P/E ratio of 10.5 based on its forward 12 month price to earnings (EPS) of $5.52 per share
Its Price to Book (P/B) ratio is 3.49 compared to its sector average of None
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.